GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hansen Medical Inc (NAS:HNSN) » Definitions » EBITDA

Hansen Medical (Hansen Medical) EBITDA : $-38.82 Mil (TTM As of Mar. 2016)


View and export this data going back to 2006. Start your Free Trial

What is Hansen Medical EBITDA?

Hansen Medical's EBITDA for the three months ended in Mar. 2016 was $-7.72 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 was $-38.82 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

Hansen Medical's EBITDA per Share for the three months ended in Mar. 2016 was $-0.41. Its EBITDA per share for the trailing twelve months (TTM) ended in Mar. 2016 was $-2.22.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.


Hansen Medical EBITDA Historical Data

The historical data trend for Hansen Medical's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansen Medical EBITDA Chart

Hansen Medical Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -12.78 -15.26 -48.71 -46.87 -39.85

Hansen Medical Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.74 -9.70 -8.64 -12.77 -7.72

Competitive Comparison of Hansen Medical's EBITDA

For the Medical Instruments & Supplies subindustry, Hansen Medical's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansen Medical's EV-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Hansen Medical's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Hansen Medical's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Hansen Medical's EBITDA for the fiscal year that ended in Dec. 2015 is calculated as

Hansen Medical's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2015, Hansen Medical's EBITDA was $-39.85 Mil.

Hansen Medical's EBITDA for the quarter that ended in Mar. 2016 is calculated as

Hansen Medical's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Mar. 2016, Hansen Medical's EBITDA was $-7.72 Mil.

EBITDA for the trailing twelve months (TTM) ended in Mar. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-38.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Hansen Medical  (NAS:HNSN) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Hansen Medical EBITDA Related Terms

Thank you for viewing the detailed overview of Hansen Medical's EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansen Medical (Hansen Medical) Business Description

Traded in Other Exchanges
N/A
Address
Hansen Medical Inc, formerly known as AutoCath Inc, was incorporated in Delaware in 2002. The Company completed its initial public offering on February 28, 2014. The Company develops, manufactures and sells medical robotics designed for accurate positioning, manipulation and stable control of catheters and catheter-based technologies. Its products include Sensei Robotic Catheter System, Magellan Robotic System, Artisan catheter, Lynx catheter, Magellan Robotic Catheter, and CoHesion 3D Visualization Module. Sensei Robotic Catheter System, or Sensei system, is designed to allow physicians to navigate flexible catheters with solid stability and control in interventional procedures within the atrial heart chambers. This system enables physicians to direct the movements of a robotic catheter like the Company's Artisan Control Catheter and Artisan Extend Control Catheter, or Artisan catheters, and Lynx Robotic Ablation Catheter, or Lynx catheter, to an anatomical location. The Sensei system is comprised of two modules: a physician control console and a patient-side module that can be connected to procedure tables. The control console can be located inside the Electro-Physiology Laboratory, or EP lab, and close to the patient or outside the EP lab in a separate location shielded from radiation. The Company's Magellan Robotic System is a peripheral vascular interventional platform that, used in combination with the Magellan Robotic Catheters, has the potential to provide endovascular specialists with vessel navigation, catheter stability during the manual delivery and placement of therapeutic devices, reduced procedural radiation exposure and fatigue, and precise robotic control of distal catheter tips. Magellan Robotic System is comprised of two modules: a physician control console and a patient-side robotic arm that can be connected to procedure tables. The Artisan catheter is a disposable catheter and guide catheter assembly that consists of a telescoping set of control catheters that are integrated to provide the desired motion of the tip of a diagnostic or therapeutic catheter that is inserted through the center lumen of the Artisan catheter. This is designed to accurately control the movement of a third party catheter chosen by the physician. CoHesion 3D Visualization Module, or CoHesion Module, is a software interface between Sensei system and the St. Jude Medical EnSite System for EP procedures. It is designed to provide physicians with 3D visualization to augment their ability to move a catheter throughout the atria, as well as increase control over placement of the catheter in specific locations. The Company markets, sells and supports its products in the United States through a direct sales force of regional sales employees, supported by clinical account managers who provide training, clinical support and other services to customers. Outside the United States, in the European Union, it uses a combination of a direct sales for
Executives
William R Rohn director PO BOX 676367, RANCHO SANTA FE CA 92067
Christopher P. Lowe director, officer: Interim CFO 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258
Oracle Institutional Partners L P 10 percent owner 200 GREENWICH AVENUE, 3RD FLOOR, GREENWICH CT 06830
Oracle Partners Lp 10 percent owner 200 GREENWICH AVE, 3RD FL, GREENWICH CT 06830
Larry N Feinberg 10 percent owner C/O ORACLE PARTNERS L P, 200 GREENWICH AVENUE, GREENWICH CT 06830
Oracle Associates Llc 10 percent owner 200 GREENWICH AVENUE, 3RD FLOOR, GREENWICH CT 06830
Stephen L Newman director 13737 NOEL ROAD, SUITE 100, DALLAS TX 75093
Oracle Ten Fund Master, Lp 10 percent owner C/O ORACLE INVESTMENT MANAGEMENT, INC., 200 GREENWICH AVENUE, GREENWICH CT 06830
Jack W. Schuler Living Trust other: Former 10% Owner 100 NORTH FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Family Foundation Schuler other: Former 10% Owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Marjorie L. Bowen director 225 6TH STREET, MANHATTAN BEACH CA 90266
Jack W Schuler director, 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Peter J Mariani officer: Chief Financial Officer C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Bruce Barclay director
Russell C Hirsch director 435 TASSO STREET, SUITE 200, PALO ALTO CA 94301